Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 175

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 175
---
 a first commercial sale of a licensed
product, we are entitled to sell our remaining inventory of such licensed product (for which regulatory approval has been received prior to such termination) for a certain period of time. At the expiration of such period of time, WuXi Biologics may
purchase any quantities of our remaining inventory at an agreed upon price.

Interests of Aadi’s Directors and Executive Officers in the PIPE Financing

Certain directors, affiliated funds of directors, and an executive officer of Aadi have interests in the PIPE
Financing that are different from, or in addition to, the interests of Aadi stockholders generally. Certain directors, affiliated funds of directors, and an executive officer of Aadi entered into the Subscription Agreement in connection with the
PIPE Financing, and committed to purchase an aggregate of 4,577,000 shares of common stock and 8,333,000 Pre-Funded Warrants. The PIPE Investors include entities that are related to Casey Castelein,
M.D., Anupam Dalal, M.D., Behzad Aghazadeh, Ph.D. and Baiteng Zhao, who serve on our board of directors, as well as an executive officer for the year ended December 31, 2024, Bryan Ball.

Additionally, it is expected that Dr. Lennon, Mr. Giacobello and Mr. Ball will continue to serve as executive officers of Aadi following the PIPE Financing
and that all members of Aadi’s board of directors will continue to

- 112 -

serve thereon following the PIPE Financing, and that such officers and directors will continue to receive cash and other compensation (including benefits) for such services under applicable plans
and arrangements which may be funded with proceeds from the PIPE Financing.

Aadi’s board of directors was aware of and considered those interests,
among other matters, in reaching its decision to approve the PIPE Financing and related matters, including the Subscription Agreement, Registration Rights Agreement and form of Pre-Funded Warrant, and
recommend the approval of the PIPE Financing and related matters to Aadi stockholders. These interests, among other factors, may have influenced the directors and executive officers of Aadi to support or approve the PIPE Financing.

In addition, pursuant to the terms of the Subscription Agreement, the executive officers and directors of the Company have entered into “lock-up” arrangements, which generally prohibit the sale, transfer or other disposition of securities of the Company, subject to certain exceptions, until the shares and shares underlying the Pre-Funded Warrants